Completed

Phase 3
Age: 45Years - 75Years
FEMALE
ID00000559

Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2016-07-12

N/A

Participants Needed

N/A

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

To determine the effects, in postmenopausal women, of hormone replacement therapy on progression/regression of coronary heart disease, as measured by quantitative angiography.

CONDITIONS

Official Title

Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)

Who Can Participate

Age: 45Years - 75Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

Postmenopausal women with angiographically-documented coronary disease. Approximately 70 percent minority

Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

Trial Site Locations

Site Locations not provided

Location information for this trial is currently unavailable.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

N/A

Primary Purpose

PREVENTION

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein.

J G Wilcox, J Hwang, H N Hodis...

https://pubmed.ncbi.nlm.nih.gov/8986684